Acquisition Opportunity
Hilco is pleased to offer for sale the business and/or assets of an established UK-based biotechnology company specialising in the development and manufacture of specialist peptides, advanced adhesives, and bio-inspired materials (the “Company”).
The Company has developed proprietary technology for producing specialist peptides, which are used in a range of applications including cosmetics, personal care, medical products, and industrial adhesives, with technology designed to overcome traditional manufacturing challenges, enabling the production of complex peptides through more efficient and potentially cost-effective processes. Its manufacturing development has included two 750-litre fermentation batches
undertaken with a leading UK process innovation organisation.
The opportunity comprises a portfolio of proprietary manufacturing technologies, developed adhesive formulations, registered intellectual property, and extensive technical know-how, supported by research and development activities, pilot-scale manufacturing trials and established industry relationships.
Highlights
- Pilot-Scale Manufacturing Development: Technology progressed beyond laboratory-scale development, including two 750-litre fermentation batches undertaken with a leading UK process innovation organisation, supported by manufacturing protocols and technical documentation.
- Proprietary Peptide Manufacturing Technology: Developed technology designed to simplify the production of specialist peptides, offering potential cost and efficiency advantages over conventional manufacturing methods, subject to further commercial-scale development.
- Established Industry Relationships: Historical commercial and development relationships with international cosmetics, medical technology, and specialist materials businesses, alongside UK defence-related development and field trials of underwater adhesive technology. The Company is engaged in an early-stage, paid prototype development project with a US defence research organisation, with further trials scheduled for December 2026.
- Financial Performance: Reported income of approximately £244,000 in FY2026, comprising £190,000 in commercial contract revenue and £54,000 in grant funding, compared with approximately £730,000 in FY2025 (including grant funding).
- Specialist Workforce: The Company employed an average of eight staff during FY2026, supporting its research, product development, and manufacturing activities.
- Pilot-Scale Manufacturing Development: Technology progressed beyond laboratory-scale development, including two 750-litre fermentation batches undertaken with a leading UK process innovation organisation, supported by manufacturing protocols and technical documentation.
- Advanced Adhesive Technology: Developed a range of bio-inspired adhesives, including specialist formulations designed for bonding in wet and underwater conditions, with potential applications across industrial materials, marine engineering, infrastructure maintenance, and medical products.
- Cosmetics & Hair Care Applications: Developed specialist ingredients designed to improve the performance of cosmetics and hair care products, including colour retention, pigment adhesion, and transfer resistance, supported by development work with a major international cosmetics group.
- Medical Adhesive Applications: Developed technology designed to improve the performance of medical adhesives and wound care products in wet or high-humidity conditions, supported by laboratory testing and technical evaluation.
- Intellectual Property Portfolio: Granted patents relating to adhesive peptide technology, alongside a European patent application under prosecution, further UK patent application documentation, registered trade marks and proprietary manufacturing know-how.
- Multiple Commercial Applications: Technologies with potential applications across biotechnology, specialty chemicals, cosmetics, personal care, medical products, and industrial manufacturing, offering opportunities for further development and integration by established industry participants.
Available Assets
- Proprietary Peptide Manufacturing Technology: Developed peptide production platform, manufacturing processes, purification methods and associated technical know-how.
- Advanced Adhesive Technology & Formulations: Proprietary bio-inspired adhesive technologies, including specialist formulations for bonding in wet and underwater conditions, together with associated testing and development data.
- Patent Portfolio & Applications: Granted patents and patent applications relating to adhesive peptides and specialist adhesive formulations, together with associated specifications, claims, drawings, and supporting documentation.
- Peptide Designs & Product Development: Portfolio of proprietary peptide designs and developed technologies for applications across cosmetics, hair care, medical adhesives, and industrial materials.
- Manufacturing Processes & Technical Documentation: Detailed production procedures, manufacturing protocols, pilot-scale development reports and technology transfer documentation supporting further manufacturing development and potential commercialisation.
- Cosmetics & Personal Care Technology: Developed ingredients and formulations for hair adhesion, colour retention, and transfer resistance, together with associated product testing and development documentation.
- Research & Development Data: Laboratory results, product testing, experimental data, analytical methodologies and supporting technical records accumulated through the Company’s research and development activities.
- Proprietary Know-How: Extensive technical documentation covering product development, manufacturing methods, adhesive formulations, testing procedures, and associated processes.
- Brand, Goodwill & Digital Assets: Rights in the Company’s corporate and technology brands, registered trade marks, associated goodwill, domain names, website content and other digital and marketing assets.
- Commercial Relationships: Relevant customer and industry relationships, historical development projects and prospective commercial opportunities, together with any transferable contractual rights, subject to applicable third-party consents.
Sales Process
Offers are due Wednesday 25 November at 4pm GMT.
Indicative offers are invited for the business as a whole or for individual assets or technology portfolios. Alternative transaction structures may also be considered, subject to the Company’s approval.
All expressions of interest and bids are to be directed to Hilco in writing. A Bid Submission Form is available on request. Please contact Hilco to gain access to a virtual data room for further information on signing a confidentiality agreement.
Key Terms & Conditions
Hilco is acting as the exclusive agent for the Company in connection with the proposed sale of, investment in, or other transaction relating to, some or all of the Company’s business, shares, assets and/or intellectual property (the “Transaction”).
Any Transaction may be structured as a share sale, business sale, asset sale (portfolio or individual), investment, joint venture or other arrangement. The Transaction is made strictly on an “as is, where is” basis. Only such right, title, and interest (if any) as the Company may have will be transferred to a purchaser or investor. No warranties, guarantees, or representations (express or implied) are given by the Company or Hilco in respect of the business, assets, intellectual property, or any information provided. All parties must rely solely on their own inquiries, investigations, and due diligence. Any information supplied (including financial, commercial or technical information) is provided for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 10% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of Transaction.
Legal completion timelines and transaction mechanics will be agreed as part of the definitive documentation.